A fter completing, and discarding, several drafts of our response to the commentary by Dr. Wolever in this issue (1), we decided that perhaps the most useful approach would be to organize our thoughts in the form of answers to the following questions: 1) Why did Dr. Wolever write "The Glycemic Index: Flogging a Dead Horse?"? 2) Why did the Editor of Diabetes Care publish it? 3) Why were we invited to write an editorial in response to Dr. Wolevers commentary? 4) Why did we borrow the title of our response from Shakespeare? Although the answers to these questions may seem self-evident, we believe they provide a useful framework with which to put Dr. Wolevers comments in perspective.
Why did Dr. Wolever write "The Glycemic Index: Flogging a Dead Horse?"
The simplest answer is that he feels that those members of the American Diabetes Association (ADA) responsible for the position statement "Nutrition Recommendations and Principles for People With Diabetes Mellitus" (2,3) were incapable of thoughtfully evaluating available data concerning the clinical utility of the glycemic index and that their inability to do so resulted in recommendations that make it more difficult to achieve glycemic control in patients with diabetes. We hope that he has made his arguments to those responsible for the recommendations, and since there is no reason to believe that these individuals acted in a frivolous manner, we can only assume that they did not find the case for the clinical utility of glycemic index as persuasive as does Dr. Wolever. Our own view, which will be explained subsequently, is very similar to that expressed in the published recommendations. However, and more to the point, why is Dr. Wolever so disturbed by the stated position of the ADA? We doubt very much that the principles of the glycemic index are unknown to any health care professional involved in treating patients with diabetes. We also doubt that these same individuals lack the ability to make up their own minds concerning the clinical utility of the glycemic index. It seems to us that Dr. Wolever should have more faith in the good judgment of his fellow health care professionals and worry less about getting official approval for his own beliefs. For example, organizing a multicenter trial, in which similar diets are used in more than one center, might well provide the level of experimental proof that could end debate as to the clinical utility of the glycemic index. Until such information is available, it seems unseemly for Dr. Wolever to focus on "anonymous comments received from manuscript reviewers that some individuals feel that the [glycemic index] is no longer an issue and that continued interest is 'flogging a dead horse'" (1). We would suggest that although such comments might be worth grumbling about, they are hardly worth airing in Diabetes Care.
Why did the Editors of Diabetes
Care decide to publish Dr. Wolever's commentary? Since we were not privy to the basis for their decision, we can only conjecture. It cannot be because of new data; essentially all of the papers discussed by Dr. Wolever were available to those responsible for the recommendations being challenged. Did the Editors believe that the issue of the glycemic index had not been considered thoughtfully by those given responsibility to make dietary recommendations and that it was of such clinical importance that it warranted this degree of attention? Perhaps they simply were leaning over backwards to make sure that the views of those advocating wider use of the glycemic index were heard. In this context, it seems worth pointing out that a compilation of the relative glycemic index of carbohydrates has been available for at least 15 years (4), and multiple reports have been published in the intervening period devoted to its therapeutic use. As suggested previously, it seems more appropriate for those individuals who disagree with ADA position papers to perform the experiments needed to carry the day for their point of view.
3. Why was our research group asked to respond to Dr. Wolever? It seems apparent from the tone of commentary, let alone the choice of words (i.e., "the Stanford group was the first to disparage the [glycemic index]" [1] ) that we are considered by Dr. Wolever as a major obstacle to the widespread application of the glycemic index. We find it hard to accept the notion that we possess such power. More to the point, we would hope that the conclusions we have drawn from our experimental results be viewed as questioning the clinical utility of the glycemic index, not "disparaging" the concept. Indeed, we find it ironic that it was a paper from "the Stanford group" showing that equal quantities of carbohydrate-rich foods led to different plasma glucose responses (5) that provided the intellectual framework for use of the glycemic index. We found our results to be most interesting for the same reason cited in the Nutrition Recommendations, i.e., the findings served as the first in a series of publications that "challenged traditional dogma regarding food absorption rates and consequent effects" (3). We believed that 20 years ago when our original paper was published, and we believe it today. However, we are capable of keeping two thoughts in our mind at the same time: demonstrating that differences in the glycemic response can occur from ingestion of similar amounts of carbohydrate-rich food does not necessarily mean that this information will lead to useful clinical application. Obviously, based on the results of subsequent studies, we concluded that knowledge of these differences was of substantial intellectual interest but did not merit consideration as the framework of a new approach to diet recommendations for patients with diabetes. It is equally obvious that Dr. Wolever disagrees with our point of view. The experimental data relevant to this issue have been published and are available to health care professionals interested in the treatment of diabetes. In contrast to Dr. Wolever, we do not view this as a Stanford versus Toronto issue, nor do we believe that we are engaged in a campaign to deprive patients of an important therapeutic advance. Ultimately, decisions as to the therapeutic utility of the glycemic index will depend on the quality of the research evaluating this question, not from efforts to reinterpret previously published data.
4. Why did we title our editorial "Much Ado About (Almost) Nothing"? To address this issue fully, it is necessary to consider some general principles concern-ing the role of diet in the treatment of diabetes. The vast majority of patients with diabetes have NIDDM, and large numbers of these patients are overweight. Without reviewing the depressing details, we are sure that there is total agreement that we have failed miserably in our efforts to achieve and maintain weight loss in overweight patients with N1DDM and that more effective approaches to achieve weight control are by far the dietary issue of the highest priority.
The second major diet issue in our view stems from the fact that coronary heart disease ( CM ID) is the major cause of morbidity and mortality in patients with diabetes. Our understanding of why this is so remains relatively rudimentary. Although patients with diabetes do not have higher cholesterol or I.DI. cholesterol concentrations than do nondiabetic individuals, there is general agreement that efforts to lower LDL cholesterol should be pursued aggressively in those at high risk for CHD (6) . Therefore, we believe the next highest diet-related priority should be to reduce intake of saturated fat.
The next issue of importance in our view is what is the source of the calories used to replace saturated fat in order to maintain energy balance. Results of two recent meta-analyses (7, 8) have clearly indicated that the fall in LDL cholesterol is similar after replacement of saturated fat with either carbohydrate or monounsaturated and/or polyunsaturated fat. On the other hand, the effects on important manifestations of diabetes do vary as a function of the manner in which saturated fat is reduced (9-13). Specifically, plasma glucose and/or insulin will tend to increase, as will plasma triglyceride concentrations, whereas HDL cholesterol levels fall when saturated fat is replaced with carbohydrate in patients with NIDDM. In contrast, those values remain unchanged if saturated fat is replaced with monounsaturated and/or polyunsaturated fat. Since the combination of high triglycerides and a low HDL cholesterol is the characteristic dyslipidemia in patients with NIDDM (6), as well as representing a potent risk factor for CHD, we believe the third most important clinical issue in diet recommendations for diabetes is what is used to replace saturated fat.
If the above priorities are accepted, it is obvious that we are asking patients with diabetes to substantially modify their daily dietary habits. How important is it to add the additional burden of incorporating the glycemic index in their daily food pattern? This is an important issue, particularly if you believe, as we do, that the ability of the individual patient to comply with a dietary program is inversely related to the complexity of the regime. Since we do not believe that the clinical impact of the glycemic index is comparable to that associated with issues of weight control, regulation of saturated fat intake, and the relative amounts of carbohydrate and fat in the diet, we agree with the ADA recommendations that if patients with diabetes are being asked to comply with the restrictions noted above and "to be encouraged to eat a variety of foods to ensure a nutritionally balanced diet, recommending only discarding foods with a low glycemic index response severely limits food choices" (3).
Our lack of enthusiasm for the use of the glycemic index is based on the following considerations: The issue is not whether one can show that there is a statistically significant relationship between the relative glycemic index of a meal and the increase in plasma glucose response, as Dr. Wolever seems to believe, but whether or not the effort to vary the glycemic index leads to lower plasma glucose concentrations. In addressing this issue, it is also important to distinguish between a statistically significant versus a clinically relevant outcome. This distinction may not be as apparent to Dr. Wolever as it is to us in light of his statements that "if a significant difference is not observed, the responses are considered to be the same" and that "this is an inappropriate approach because the fact that no difference is detected does not necessarily mean that no difference really exists" (1). We are as aware as Dr. Wolever of the pitfalls of a type II error when the expected difference is small, and we are aware that a large number of patients must be studied in order to see a difference. However, a more relevant issue is to ask why a type II error might easily occur in studies evaluating the effect of differences in the glycemic indexes of foods. In this context, Dr. Wolever has provided some possible explanations. For example, he states that "glycemic responses are quite variable from day to day within subjects" (1). Additionally, "subtle differences in banana ripeness can double its [glycemic index]," and the "[glycemic index] of 1 inch cubes of boiled potato can be increased by 25% by mashing them" (1) . Given these caveats, it is not surprising that Dr. Wolever is concerned about the likelihood of type II errors. More importantly, if patients must be concerned about how green their bananas are or to mash or not to mash their potatoes, we would agree with Dr. Wolever that "detailed knowledge is required for detailed application of the [glycemic index], and this is probably beyond the needs and abilities of most people" (1) . Indeed, the results summarized in the table provided by Dr. Wolever suggest that application of the glycemic index may also be beyond the abilities of most investigators. For example, in one study of patients with NIDDM by the Toronto Group, a decrease in diet glycemic index of 31% led to a fall in fructosamine of 3.4% (14) , whereas in another study by the same group (15), fructosamine levels fell more than three times as much (11 vs. 3 .4%), with a similar decrease in diet glycemic index (33 vs. 31%). At the other extreme, an extremely modest decrease of 6% in diet glycemic index in patients with NIDDM in London led to a 16% decline in fructosamine (16), the best response noted in any study of patients with NIDDM. In London, it appears that less is more, if not in architecture, at least in the power of the glycemic index.
Dr. Wolever concludes his commentary by stating that his "final concern about general use of the [glycemic index] is that we do not know very much about how to use it" (1). He then goes on to list a series of important issues that he feels should be addressed. For example, "does using low-[glycemic index] starchy foods have the same effect as using low-[glycemic index] foods when the carbohydrate is predominantly sugars, such as certain fruits, yogurt, and dairy products?" (1). While we would not quarrel with the areas he considers worthy of study, we suggest that he also give a high priority to performing a multicenter study that fulfills the following criteria: I) at least some of the investigators should not have an a priori view of the clinical utility of the glycemic index; 2) the menus should be the same in all sites; and 3) the study should be carried out long enough to evaluate the clinical relevance of any change noted. We have just finished participating in such a study, focused on evaluating the clinical effects of diets varying in carbohydrate and fat content (12) , and we know that it can be done. If the results of such a study show that essentially similar clinically useful benefits can be achieved across studies, Dr. Wolever will have every reason to ask the appropriate ADA committee to reconsider their deci-sion. Until then, we believe that there is no reason to question either the intelligence or the objectivity of the members of the ADAsponsored committee, who concluded that "from a clinical perspective first priority should be given to the total amount of carbohydrate consumed rather than the source of the carbohydrate" (3). 
